Indication expansion

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

Applying theoretical physics to Longevity drug discovery

Peter Fedichev's Gero raising $10 million for anti-aging drug discovery and clinical trials. The use of AI in Longevity drug discovery is nothing new, Insilico...

Longevity and the art of motorcycle maintenance

OpenCures' Kevin Perrott talks about empowering the consumer with their own health data. One of the Longevity sector’s leading voices came to the field relatively...

Longevity2020: Day 5 Recap

On Friday, the Longevity2020 online conference drew to a close, and the final day explored what people can be doing today to address their...

BioAge licenses HIF-PH inhibitor to treat aging

BioAge's human aging data platform demonstrates that HIF pathway is linked to healthspan and lifespan. Longevity focused biotech firm BioAge Labs has announced an exclusive...

Longevity2020: Day 3 recap

Experts, innovators, investors and the curious meet online in the biggest Longevity conference ever staged. As we enter the fourth day of Longevity2020, we thought...

Longevity2020: Day 2 recap

Yesterday at Longevity2020 was all about rejuvenation therapies, bringing together some of the world’s leading luminaries in the fight against aging. Things kicked off with...

Building faster and better age-related clinical trials

Prof Ilaria Bellantuono seeks to build faster, better clinical trials for age-related disease with a focus on frailty. Multimorbidity – an individual suffering two or...

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. Longevity.Technology: When it comes to the world of Longevity...

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. Longevity.Technology: The curator on Thursday 30th April...

Low-dose rapamycin to protect elderly from COVID-19

Longevity researcher proposes clinical trials for low-dose rapamycin (and other geroprotectors) to protect the elderly from COVID-19. The UK's Biogerontology Research Foundation today announced the...

Chemical screening to find hidden Longevity gems?

Start-up NemaLife evolves from platform technology to services provider to identify chemicals that have both positive and negative effects on Longevity. The use of the...

From machines to animals to humans

Exclusive with Prof Joao Pedro de Magalhaes: talking AI, indication expansion and animal models. “Will you still need me, will you still feed me, when...

Metabolic aging, fasting and metformin

The presence of a “metabolic clock” that regulates aging involves the accumulation of metabolic alterations and a decline in metabolic homeostasis and biological fitness. An...

LSD = Longevity (and) stalled dementia?

New York-based biotech company Eleusis has completed a phase 1 trial of the psychedelic drug LSD and is moving forward to phase 2. Could...

Fishing for regenerative therapies

Talking Longevity, indication expansion, killifish and regeneration with Dr Aric Rogers from the MDI Biological Laboratory. Nestled on the picturesque coastline of Maine, USA, the...

Rejuvant shows positive early results in humans

Anecdotal results for dietary supplement show significant improvements in biological age and major reductions in key blood biomarkers. In our recent interview with leading Longevity...

Prof Brian Kennedy: Talking biomarkers and interventions

“We're not trying to make billionaires live longer, we're trying to make everybody live longer.” When it comes to thought leaders in the Longevity sector,...

Talking pipeline with resTORbio’s Joan Mannick

While Phase 3 trial of RTB101 for respiratory illness did not meet primary endpoint, company presses-on with Parkinson’s trial for TORC1 inhibitor: Results expected...

It’s all in the numbers; small sets of numbers

AI start-up NetraMark targets $3 million seed round while identifying that an exciting repurposing candidate has potential for indication expansion into Longevity. “I won’t tell you...

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...